piperidines and Asthma--Exercise-Induced

The potential for rimiterol to protect athletes from exercise-induced asthma (EIA) has not been fully established. Ten athletes with asthma (15 to 30 years of age) undertook 8 minutes of submaximal exercise (80% of anaerobic threshold) on the treadmill ergometer, once after inhaling rimiterol and once after inhaling a placebo. Treatment with all bronchodilator drugs was stopped for the 12 hours preceding each exercise test. Two puffs (400 micrograms) of rimiterol or placebo were administered in a double-blind crossover manner 2 minutes before each exercise test. Lung function measurements were made before exercise and immediately, 5, 10, 15, 20, 25, and 30 minutes after completion of exercise. The results of a two-way analysis of variance revealed significant (p less than 0.01) difference in the FEV1 scores obtained after rimiterol inhalation and placebo inhalation, 5, 10, 15, 20, 25, and 30 minutes after cessation of exercise. After inhalation of rimiterol, there were no significant changes in FEV1. After inhaling the placebo, significant reductions (p less than 0.01) in FEV1 occurred after cessation of exercise (5, 10, 15, and 20 minutes). All subjects exhibited EIA after placebo, and none after rimiterol. The mean maximum drop after exercise in FEV1 after inhalation of rimiterol (2.807 +/- 5.55) and placebo (24.54 +/- 8.4) was significantly different (t = 6.849). It was concluded that inhalation of rimiterol 2 minutes before exercise afforded significant protection from EIA in all subjects tested.

Topics: Administration, Inhalation; Adolescent; Adult; Asthma; Asthma, Exercise-Induced; Catechols; Double-Blind Method; Exercise Test; Female; Forced Expiratory Volume; Humans; Male; Piperidines; Sports

Topics: Adolescent; Asthma; Asthma, Exercise-Induced; Bronchodilator Agents; Child; Child, Preschool; Cromolyn Sodium; Humans; Ketotifen; Piperidines; Thiophenes

We studied 17 patients in a double-blind controlled trial to see if ketotifen, a new oral mast-cell stabilizing agent, would protect against bronchoconstriction induced by exercise on a treadmill. In addition eight of the patients also completed exercise tests without previous medication and again after inhalation of disodium cromoglycate (DSCG). The greatest amount of bronchoconstriction was caused by exercise without preliminary treatment. There was less bronchoconstriction after ketotifen, but this was no better than a placebo. DSCG provided significant protection. We were unable to confirm previous reports that ketotifen is as effective as DSCG in preventing exercise-induced asthma.

Topics: Adolescent; Adult; Asthma; Asthma, Exercise-Induced; Clinical Trials as Topic; Cromolyn Sodium; Double-Blind Method; Female; Humans; Ketotifen; Male; Middle Aged; Peak Expiratory Flow Rate; Piperidines; Thiophenes

Seven young extrinsic asthmatics participated in an open, pilot study to determine the protective effect of a selective 5-hydroxytryptamine (5-HT) blocking agent, ketanserin, on exercise induced asthma. Ketanserin in a dose of 10 mg given intravenously 20 min before exercise altered the basal bronchomotor tone in only 1 of 6 subjects and offered partial protection against exercise-induced bronchoconstriction in 1 of 5 asthmatics with no overall effect in the group. All patients experienced sleepiness after administration of ketanserin and one had bradycardia with hypotension. The ineffectiveness of ketanserin suggests indirectly that serotonin has a limited role in the pathogenesis of exercise-induced asthma.

Topics: Adolescent; Adult; Asthma; Asthma, Exercise-Induced; Bronchi; Child; Humans; Ketanserin; Piperidines; Receptors, Serotonin; Sleep Stages

Topics: Asthma; Asthma, Exercise-Induced; Cromolyn Sodium; Humans; Ketotifen; Piperidines; Thiophenes

Topics: Asthma; Asthma, Exercise-Induced; Child; Cromolyn Sodium; Humans; Ketotifen; Piperidines; Thiophenes